STOCK TITAN

Trevena Reports Third Quarter 2024 Results and Provides Business Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Negative)
Tags

Trevena Inc (TRVN) reported Q3 2024 financial results with a net loss of $4.9 million ($5.79 per share), compared to $7.9 million in Q3 2023. The company secured a $2 million non-dilutive financing from R-Bridge Healthcare Fund, with potential for additional $8 million based on milestones. Following a 1-for-25 reverse stock split in August 2024, TRVN was delisted from Nasdaq and began trading on OTC Pink Sheets. The company implemented significant cost-cutting measures, including executive terminations, reducing to four employees, and multiple board resignations. Cash position stood at $13.5 million as of September 30, 2024.

Trevena Inc (TRVN) ha riportato i risultati finanziari del terzo trimestre 2024 con una perdita netta di 4,9 milioni di dollari (5,79 dollari per azione), rispetto a 7,9 milioni nel terzo trimestre 2023. L'azienda ha ottenuto un finanziamento non diluitivo di 2 milioni di dollari dal R-Bridge Healthcare Fund, con la possibilità di ulteriori 8 milioni di dollari in base a traguardi. Dopo uno split azionario inverso 1-per-25 nell'agosto 2024, TRVN è stata esclusa dal Nasdaq e ha iniziato a trattare nelle OTC Pink Sheets. L'azienda ha attuato significative misure di riduzione dei costi, comprese le terminazioni esecutive, riducendo il numero di dipendenti a quattro e diverse dimissioni dal consiglio di amministrazione. La posizione di cassa ammontava a 13,5 milioni di dollari al 30 settembre 2024.

Trevena Inc (TRVN) reportó los resultados financieros del tercer trimestre de 2024 con una pérdida neta de 4,9 millones de dólares (5,79 dólares por acción), en comparación con 7,9 millones en el tercer trimestre de 2023. La compañía aseguró un financiamiento no dilutivo de 2 millones de dólares del R-Bridge Healthcare Fund, con potencial para obtener otros 8 millones de dólares basado en hitos. Tras una división inversa de acciones de 1 por 25 en agosto de 2024, TRVN fue excluida del Nasdaq y comenzó a cotizar en las OTC Pink Sheets. La empresa implementó medidas significativas de reducción de costos, incluyendo despedidos ejecutivos, reduciendo el personal a cuatro empleados, y varias renuncias del consejo. La posición de efectivo era de 13,5 millones de dólares al 30 de septiembre de 2024.

Trevena Inc (TRVN)은 2024년 3분기 재무 결과를 발표했으며, 490만 달러 (주당 5.79달러)의 순손실을 기록했습니다. 이는 2023년 3분기의 790만 달러에 비해 감소한 것입니다. 회사는 R-Bridge Healthcare Fund로부터 200만 달러의 비희석 자금을 확보했으며, 이를 통해 이정표 달성에 따라 추가적으로 800만 달러를 받을 가능성이 있습니다. 2024년 8월 1 대 25 주식 분할 이후, TRVN은 나스닥에서 상장 폐지되었으며 OTC Pink Sheets에서 거래를 시작했습니다. 회사는 임원 해고를 포함한 대규모 비용 절감 조치를 시행하여 직원 수를 4명으로 줄이고, 여러 이사직 사퇴를 발표했습니다. 2024년 9월 30일 기준으로 현금 보유액은 1350만 달러였습니다.

Trevena Inc (TRVN) a rapporté les résultats financiers du troisième trimestre 2024 avec une perte nette de 4,9 millions de dollars (5,79 dollars par action), contre 7,9 millions de dollars au troisième trimestre 2023. L'entreprise a sécurisé un financement non dilutif de 2 millions de dollars auprès du R-Bridge Healthcare Fund, avec un potentiel d'un supplément de 8 millions de dollars en fonction des étapes atteintes. Suite à une division d'actions inversée de 1 pour 25 en août 2024, TRVN a été radiée du Nasdaq et a commencé à se négocier sur les OTC Pink Sheets. L'entreprise a mis en œuvre d'importantes mesures de réduction des coûts, y compris des licenciements d'exécutifs, réduisant le nombre d'employés à quatre, et plusieurs démissions au conseil d'administration. La position de liquidités était de 13,5 millions de dollars au 30 septembre 2024.

Trevena Inc (TRVN) hat die finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht, mit einem Nettverlust von 4,9 Millionen Dollar (5,79 Dollar pro Aktie), verglichen mit 7,9 Millionen Dollar im dritten Quartal 2023. Das Unternehmen sicherte sich eine nicht verwässernde Finanzierung von 2 Millionen Dollar vom R-Bridge Healthcare Fund, mit der Möglichkeit für zusätzliche 8 Millionen Dollar basierend auf Meilensteinen. Nach einem Rücksplit von 1 zu 25 im August 2024 wurde TRVN von der Nasdaq delistet und begann mit dem Handel auf OTC Pink Sheets. Das Unternehmen führte erhebliche Kostensenkungsmaßnahmen durch, darunter die Entlassung von Führungskräften, und reduzierte die Mitarbeiterzahl auf vier, sowie mehrere Rücktritte im Vorstand. Die Liquiditätsposition betrug zum 30. September 2024 13,5 Millionen Dollar.

Positive
  • Reduced net loss to $4.9M in Q3 2024 from $7.9M in Q3 2023
  • Secured $2M non-dilutive financing with potential for additional $8M
  • R-Bridge agreed to forgive $10M of outstanding debt
  • Significant cost reduction through executive terminations and board resignations
Negative
  • Delisted from Nasdaq due to non-compliance with minimum stockholder's equity requirement
  • Moved to OTC Pink Sheets, potentially reducing stock liquidity and investor access
  • Reduced workforce to only four employees
  • Ongoing strategic review including possible sale or wind down of company

Insights

The Q3 2024 results reveal a company in significant financial distress, undertaking dramatic restructuring efforts. Key concerns include:

  • Delisting from Nasdaq and move to OTC Pink Sheets indicates severe market deterioration
  • Massive executive restructuring with termination of key leadership (CEO, CMO, CFO) and board member resignations
  • Workforce reduction to just 4 employees signals extreme cost-cutting
  • Despite $13.5M cash position and reduced quarterly loss of $4.9M vs $7.9M YoY, the company is actively exploring sale/merger options
  • The $10M debt forgiveness through troubled debt restructuring reflects serious financial strain

The strategic review and potential sale/wind-down considerations suggest the company's standalone viability is questionable. The 1-for-25 reverse split and OTC migration significantly impact investor accessibility and liquidity.

CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates.

Third Quarter 2024 and Recent Corporate Updates

  • $2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a non-dilutive, $2 million tranche in connection with an amendment (the “Amendment”) to its existing ex-US royalty financing with R-Bridge Healthcare Fund (“R-Bridge”). The Company is further eligible to receive up to an additional $8 million based on future milestones. As part of the Amendment, (i) certain OLINVYK Chinese IP that had been previously pledged to R-Bridge under the Royalty Financing was transferred to R-Bridge, (ii) warrants previously issued to R-Bridge as part of the Royalty Financing were amended to reduce the exercise price to a 15% premium to the then-current stock price and to extend the exercise period to five years from the effective date of the Amendment, (iii) the existing cap on the US royalty payable to R-Bridge was increased from $10 million to $12 million (with no minimum or fixed payments), and (iv) R-Bridge agreed to forgive $10.0 million of the amount that was outstanding to them prior to the Amendment. This $10.0 million forgiveness was determined to be a troubled debt restructuring and therefore no gain will be recognized by the Company for accounting purposes.
  • Reverse Stock Split. In August 2024 the Company effected a 1-for-25 reverse stock of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, each 25 shares of the Company’s issued and outstanding common stock were automatically combined into one validly issued, fully paid and non-assessable share of common stock. In addition, proportional adjustments were made to the number of shares of the Company’s common stock issuable under the Company’s equity incentive plans and all outstanding securities and other rights convertible or exercisable into shares of the Company’s common stock, including all stock options and warrants outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split did not have any effect on the stated par value of the Company’s common stock.
  • Nasdaq Delisting and Subsequent Initiation of Trading on OTC Pink Sheets. On October 4, 2024, the Company announced that it had received notice that the Nasdaq Hearings Panel (the “Panel”) had determined to delist the Company’s common stock from The Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s failure to comply with the minimum stockholder’s equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard Rule”). As previously disclosed, the Panel had provided the Company until October 2, 2024, to regain compliance with the Equity Standard Rule. Trading in the Company’s common stock was suspended on Nasdaq effective with the open of business on October 8, 2024, and the Company’s common stock began trading on the Pink Open Market operated by the OTC Markets Group, Inc. (commonly referred to as the “pink sheets”) on October 8, 2024 under the trading symbol “TRVN.”
  • Additional Cost-Cutting Measures. On October 5, 2024, in connection with certain cost-cutting measures, the Board of Directors (“the Board”) approved the termination of employment, without cause, of three senior executives: Carrie Bourdow (President & CEO), Mark Demitrack (SVP & CMO), and Barry Shin (EVP & COO/CFO). The terminations did not involve any disagreement concerning the Company’s operations, policies or practices, and the Board thanked these executives for their service to the Company. Following the effectiveness of these terminations, Ms. Bourdow continues to serve as Chairman of the Board and Acting CEO; Mr. Demitrack continues to serve as Acting CMO; Mr. Shin continues to serve as Acting COO/CFO; and all entered into consulting agreements with the Company. Following these cost-cutting measures, the Company has four employees.  

  • Resignation of Certain Directors. On November 5, 2024, in connection with the ongoing cost-cutting measures, Mark Corrigan, M.D.; Marvin H. Johnson, Jr.; Jake R. Nunn; and Anne M. Phillips each informed the Company of his or her intent to resign from the Board and the committees thereof, effective as of November 5, 2024. None of these resignations was related to any disagreement with the Company over any of its operations, policies or practices. Carrie Bourdow continues to serve as Chairman of the Board and Scott Braunstein, M.D. and Barbara Yanni continue to serve as directors of the Company.

  • Continued Strategic Review. The Company continues its review of strategic alternatives, including for OLINVYK, TRV045 and its other pipeline assets. There can be no assurance regarding the schedule for completion of the strategic review process, that this strategic review process will result in the Company pursuing any transaction or that any transaction, if pursued, will be completed. Potential strategic alternatives that may be explored or evaluated include, but are not limited to, a sale, license, divestiture or discontinuation of US commercial sales of OLINVYK; a sale, license or divestiture of our pipeline assets; or a sale, merger or wind down of the Company.

Financial Results and Other Updates for Third Quarter 2024
For the third quarter of 2024, the Company reported a net loss attributable to common stockholders of $4.9 million, or $5.79 per share, compared to $7.9 million, or $14.20 per share in the third quarter of 2023. Cash and cash equivalents were $13.5 million as of September 30, 2024.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.

For more information, please visit www.Trevena.com 

About TRV045

TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy.

S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability.

Trevena's discovery efforts have identified a family of compounds that are highly selective for the S1P1 receptor. TRV045 reversed thermal hyperalgesia, a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. TRV045 was not associated with lymphopenia and produced no changes in blood pressure, heart rate, or respiratory function at or above pharmacologically active doses in nonclinical studies. TRV045 is an investigational product and is not yet approved by the FDA. Subjects in both studies referenced in this press release were enrolled outside of the United States, and the studies were not conducted under the Investigational New Drug Application for TRV045.

About OLINVYK® (oliceridine) injection

OLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1 mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE

OF OLINVYK

Addiction, Abuse, and Misuse

Because the use of OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of OLINVYK, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of OLINVYK are essential.

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of OLINVYK and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.

Neonatal Opioid Withdrawal Syndrome

If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.

INDICATIONS AND USAGE

OLINVYK is an opioid agonist indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Limitations of Use

Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, reserve OLINVYK for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:

  • Have not been tolerated or are not expected to be tolerated.
  • Have not provided adequate analgesia or are not expected to provide adequate analgesia.

The cumulative total daily dose should not exceed 27 mg.

CONTRAINDICATIONS

OLINVYK is contraindicated in patients with:

  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Known hypersensitivity to oliceridine (e.g. anaphylaxis)

WARNINGS AND PRECAUTIONS

  • OLINVYK contains oliceridine, a Schedule II controlled substance, that exposes users to the risks of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed OLINVYK. Assess risk, counsel, and monitor all patients receiving opioids.
  • Serious, life-threatening respiratory depression has been reported with the use of opioids, even when used as recommended, especially in patients with chronic pulmonary disease, or in elderly, cachectic and debilitated patients. The risk is greatest during initiation of OLINVYK therapy, following a dose increase, or when used with other drugs that depress respiration. Proper dosing of OLINVYK is essential, especially when converting patients from another opioid product to avoid overdose. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status.
  • Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia with risk increasing in a dose-dependent fashion. In patients who present with CSA, consider decreasing the dose of opioid using best practices for opioid taper.
  • Profound sedation, respiratory depression, coma, and death may result from the concomitant use of OLINVYK with benzodiazepines and/or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, or alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate, prescribe the lowest effective dose, and minimize the duration.
  • Use of OLINVYK for an extended period of time during pregnancy can result in withdrawal in the neonate that may be life-threatening. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
  • OLINVYK was shown to have mild QTc interval prolongation in thorough QT studies where patients were dosed up to 27 mg. Total cumulative daily doses exceeding 27 mg per day were not studied and may increase the risk for QTc interval prolongation. Therefore, the cumulative total daily dose of OLINVYK should not exceed 27 mg.
  • Increased plasma concentrations of OLINVYK may occur in patients with decreased Cytochrome P450 (CYP) 2D6 function or normal metabolizers taking moderate or strong CYP2D6 inhibitors; also in patients taking a moderate or strong CYP3A4 inhibitor, in patients with decreased CYP2D6 function who are also receiving a moderate or strong CYP3A4 inhibitor, or with discontinuation of a CYP3A4 inducer. These patients may require less frequent dosing and should be closely monitored for respiratory depression and sedation at frequent intervals. Concomitant use of OLINVYK with CYP3A4 inducers or discontinuation of a moderate or strong CYP3A4 inhibitor can lower the expected concentration, which may decrease efficacy, and may require supplemental doses.
  • Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. This differs from tolerance where increasing doses are required to maintain the desired effect. Symptoms of OIH include, but may not be limited to, increased levels of pain upon dose increase, decreased levels of pain upon dose decrease, or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only if there is no evidence of disease progression, opioid tolerance, withdrawal, or addictive behavior. If OIH is suspected, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation.
  • Cases of adrenal insufficiency have been reported with opioid use (usually greater than one month). Presentation and symptoms may be nonspecific and include nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If confirmed, treat with physiologic replacement doses of corticosteroids and wean patient from the opioid.
  • OLINVYK may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients for signs of hypotension. In patients with circulatory shock, avoid the use of OLINVYK as it may cause vasodilation that can further reduce cardiac output and blood pressure.  
  • Avoid the use of OLINVYK in patients with impaired consciousness or coma. OLINVYK should be used with caution in patients who may be susceptible to the intracranial effects of CO2 retention, such as those with evidence of increased intracranial pressure or brain tumors, as a reduction in respiratory drive and the resultant CO2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy.
  • As with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
  • OLINVYK may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures in vulnerable patients. Monitor patients with a history of seizure disorders for worsened seizure control.
  • Do not abruptly discontinue OLINVYK in a patient physically dependent on opioids. Gradually taper the dosage to avoid a withdrawal syndrome and return of pain. Avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving OLINVYK, as they may reduce the analgesic effect and/or precipitate withdrawal symptoms.
  • OLINVYK may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery.
  • Although self-administration of opioids by patient-controlled analgesia (PCA) may allow each patient to individually titrate to an acceptable level of analgesia, PCA administration has resulted in adverse outcomes and episodes of respiratory depression. Health care providers and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects of opioid medications.

ADVERSE REACTIONS

Adverse reactions are described in greater detail in the Prescribing Information.

The most common (incidence ≥10%) adverse reactions in Phase 3 controlled clinical trials were nausea, vomiting, dizziness, headache, constipation, pruritus, and hypoxia.

MEDICAL INFORMATION

For medical inquiries or to report an adverse event, other safety-related information or product complaints for a company product, please contact the Trevena Medical Information Contact Center at 1-844-465-4686 or email MedInfo@Trevena.com.

You are encouraged to report suspected adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

PLEASE see www.OLINVYK.com for full prescribing information including BOXED warning and important safety information

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the expectations surrounding the continued advancement of the Company’s product pipeline; the potential safety and efficacy of the Company’s product candidates and their regulatory and clinical development; the Company’s intention to pursue strategic alternatives for OLINVYK and the ability of any such strategic alternative to provide shareholder value; the expected financial and operational impacts of the Company’s decision to reduce commercial support for OLINVYK; the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of discussions with FDA; available funding; uncertainties related to continued listing on NASDAQ; uncertainties related to the Company’s intellectual property; uncertainties related to other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

For more information, please contact:

Company Contact:

Bob Yoder
SVP, Chief Business Officer & Head of Commercial Operations
Trevena, Inc.
(610) 354-8840


TREVENA, INC. 
Condensed Statements of Operations 
(Unaudited, in thousands except share and per share data) 
          
  Three Months Ended Sept 30, Nine Months Ended Sept 30, 
   2024   2023   2024   2023  
          
Product revenue $(21) $1  $13  $28  
License revenue  304   179   615   3,179  
Total revenue  283   180   628   3,207  
          
Operating expenses:         
Cost of goods sold  114   175   305   389  
Selling, general and administrative  3,880   4,572   13,323   15,799  
Research and development  1,866   4,260   8,958   12,160  
Total operating expenses  5,860   9,007   22,586   28,348  
Loss from operations  (5,577)  (8,827)  (21,958)  (25,141) 
Other income  638   897   4,450   1,380  
Net loss $(4,939) $(7,930) $(17,508) $(23,761) 
          
Per share information:         
Net loss per share of common stock, basic and diluted ($5.79) ($14.20) ($20.54) ($50.65) 
Weighted average shares outstanding, basic and diluted 852,801   558,564   852,253   469,149  
          



TREVENA, INC.
Condensed Balance Sheets
(Unaudited, in thousands)
     
  September 30, 2024December 31, 2023
Assets    
Current assets:    
Cash and cash equivalents $13,462  $32,975 
Restricted cash  282   - 
Prepaid expenses and other current assets  991   2,230 
Total current assets  14,735   35,205 
Restricted cash, net of current portion  340   540 
Property and equipment, net  923   1,195 
Right-of-use lease assets  3,190   3,665 
Total assets $19,188  $40,605 
     
Liabilities and stockholders’ (deficit) equity    
Current liabilities:    
Accounts payable, net $918  $2,303 
Accrued expenses and other current liabilities  3,164   4,239 
Current portion of loans payable, net  902   - 
Lease liabilities  1,102   1,012 
Total current liabilities  6,086   7,554 
Loans payable, net  31,972   30,809 
Leases, net of current portion  3,588   4,424 
Warrant liability  851   5,475 
Total liabilities  42,497   48,262 
     
Common stock  1   1 
Additional paid-in capital  582,259   580,403 
Accumulated deficit  (605,569)  (588,061)
Total stockholders’ (deficit) equity  (23,309)  (7,657)
Total liabilities and stockholders’ (deficit) equity $19,188  $40,605 
     

FAQ

What was Trevena's (TRVN) net loss in Q3 2024?

Trevena reported a net loss of $4.9 million ($5.79 per share) in Q3 2024, compared to $7.9 million in Q3 2023.

Why was Trevena (TRVN) delisted from Nasdaq in October 2024?

Trevena was delisted from Nasdaq due to failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1).

What financing did Trevena (TRVN) receive in July 2024?

Trevena received a $2 million non-dilutive financing tranche from R-Bridge Healthcare Fund, with eligibility for up to $8 million additional based on future milestones.

What cost-cutting measures did Trevena (TRVN) implement in October 2024?

Trevena terminated three senior executives, reduced workforce to four employees, and had multiple board members resign as part of cost-cutting measures.

TREVENA INC

OTC:TRVN

TRVN Rankings

TRVN Latest News

TRVN Stock Data

1.27M
850.00k
0.38%
8.78%
6.96%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHESTERBROOK